Fidelity SPDR Advertisement
Home > Boards > Free Zone > User's Groups > Mohacsy's Safe Portfolio Member Forum

Orphan Drug Status doesn't assure FDA approval of

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
n4807g Member Profile
Member Level 
Followed By 31
Posts 26,943
Boards Moderated 0
Alias Born 07/08/03
160x600 placeholder
Cbo Offers Mixed Forecast Of U.s. Budget, Economy
The Congressional Budget Office said the federal budget deficit over the next decade will be smaller than previously forecast, as the government continues to benefit from low interest rates.
More Top Equities Stories Of The Day
Bouygues Falls After Warning; Essilor Rallies: Europe Movers
BofA Settlement Earmarks $7 Billion for Homeowners
Stocks Drift Between Gains, Losses
ArcelorMittal Climbs; Antofagasta Slides: European Movers
Islamic State Leaves Trail on Social Media
Facebook Leads Tech Stocks Lower
European Stocks Pause as Investors Still Mull Draghi's Hint at Stimulus -- Update
Communications Equipment Maker Comtech Mulls Sale -Reuters
n4807g Member Level  Monday, 04/23/12 12:16:00 PM
Re: FullBoogie post# 60301
Post # of 67995 
Orphan Drug Status doesn't assure FDA approval of the compound being evaluated, it confers certain marketing advantages and tax credits should the drug be approved.

Like most small biotechs CYTR will succeed or fail on the technology they employ. In CYTR's case the delivery system. The near term future of INNO-206 will be clear when they report interim findings of their ongoing 2b trial.

Like all biotechs this is a speculative investment, but I've watched many companies with similar strategies do well. The preliminary data look promising (no guarantee) but as I said in my previous post Abraxane uses Albumin as the entry vehicle in tumors and CYTR uses the same concept.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist